ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 526

Use of a Novel Probe to Demonstrate Granzyme B Activity in Sjogren’s Syndrome Salivary Glands

Kimberly Doering Maurer1, Laura Gutierrez-Alamillo1, Efstathia K. Kapsogeorgou2, Athanasios G. Tzioufas3, Livia Casciola-Rosen4 and Antony Rosen4, 1Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, 2Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, 3Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, 4Division of Rheumatology, Johns Hopkins University, Baltimore, MD

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Sjögren's Syndrome - Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Salivary glands are a prominent target organ in Sjögren’s   syndrome (SS), with patients having abnormal secretory function and inflammatory infiltration of these glands.  Little is currently known about the mechanisms whereby the immune system contributes to ongoing tissue damage and dysfunction in this disease.  IRF1 is one of the most efficiently cleaved granzyme B substrates ever defined. The purpose of this study was to define whether cytotoxic lymphocytes in the gland actively induce proteolysis in salivary gland epithelial cells in situ by using an antibody highly specific for granzyme B (GrB)-cleaved IRF-1 to probe for activity of the GrB pathway in vivo in SS salivary gland biopsies.

Methods: Immunohistochemical staining of salivary gland paraffin sections was used to assess the presence of CD8 infiltrates, and the extent of GrB staining.  Lysates generated from frozen salivary gland biopsies were immunoblotted to detect CD8 and IRF1 expression.  35S-methionine labeled IRF1 was generated by in vitro transcription and translation, and was used to demonstrate cleavability by GrB, and as a template for site-directed D204A mutagenesis  to confirm the GrB cleavage site in IRF1.  Using this information, an antibody detecting exclusively the N-terminal GrB cleaved IRF1 fragment (R6017) (and not the intact molecule) was generated.  This antibody was carefully validated and used for immunohistochemistry and immunoblotting on salivary gland tissue and lysates obtained from SS patients. 

Results: CD8 infiltrates were prominent in ~60% of SS salivary glands by immunoblotting and immunohistochemistry. IRF1 is expressed at high levels in SS salivary glands, but not control salivary glands.  IRF1 is efficiently cleaved by GrB at D204.  Using the antibody R6017 that is highly specific for the N-terminal fragment generated by GrB cleavage, we demonstrated the presence of GrB-induced fragments by immunoblotting and immunohistochemistry performed on SS patient but not control salivary gland tissue.

Conclusion:   These studies provide the first direct in vivo evidence that the cytotoxic lymphocyte granule pathway is actively modifying salivary epithelial cells in patients with SS. Defining granzyme-induced effects on salivary epithelial function may provide important understanding of the mechanisms of salivary epithelial function in this disease, with therapeutic implications.


Disclosure:

K. Doering Maurer,
None;

L. Gutierrez-Alamillo,
None;

E. K. Kapsogeorgou,
None;

A. G. Tzioufas,
None;

L. Casciola-Rosen,
None;

A. Rosen,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/use-of-a-novel-probe-to-demonstrate-granzyme-b-activity-in-sjogrens-syndrome-salivary-glands/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology